This flowchart outlines patient selection. CTA indicates computed tomography angiography; PROMISE, the Prospective Multicenter Imaging Study for Evaluation of Chest Pain.
A, Kaplan-Meier estimates stratified by the presence of high-risk plaque (HRP), adjusted for significant stenosis [SS], defined as 70% or greater stenosis in any coronary artery or 50% or greater stenosis in the left main coronary artery and for atherosclerotic cardiovascular disease risk score. B, Kaplan-Meier estimates stratified by both the presence of HRP and SS with adjustment for atherosclerotic cardiovascular disease risk score. The absolute number of patients with high relative risk of major adverse cardiovascular events (MACE) was low. Only 105 patients (2.3%) had SS without high-risk plaque, and 171 patients (3.9%) had both SS and HRP.
The analyses demonstrate the predictive value of high-risk plaque for the outcome of major adverse cardiovascular events (death, nonfatal myocardial infarction, or hospitalization for unstable angina) adjusted for significant stenosis (≥70% stenosis in any coronary artery or ≥50% in the left main coronary artery) and atherosclerotic cardiovascular disease risk score. Error bars show adjusted hazard ratios with 95% CIs, adjusted for atherosclerotic cardiovascular disease risk score and significant stenosis. Wide and overlapping 95% CIs were present. The median age of participants was 59.6 years; median body mass index (BMI; calculated as weight in kilograms divided by height in meters squared), 29.5.
eFigure 1. Evaluation of Coronary CTA Datasets for the Detection of Coronary Plaque, Stenosis, and High-risk Plaque Features
eFigure 2. Kaplan–Meier Estimates of the Composite Secondary End Point of Cardiovascular Death, Myocardial Infarction, or Hospitalization for Unstable Angina and Tertiary End Point of Death, or Myocardial Infarction as a Function of Time After Randomization.
eFigure 3. Major Adverse Cardiovascular Event Rate (Death, Non-Fatal Myocardial Infarction, or Hospitalization for Unstable Angina) Stratified by the Degree of Stenosis and Presence of High-Risk Plaque
eTable 1. Results of Univariable and Multivariable Cox Proportional Hazard Analysis Demonstrating the Predictive Value of High-Risk Plaque for the Outcome of Major Adverse Cardiovascular Events (Death, Non-Fatal Myocardial Infarction, or Hospitalization for Unstable Angina Pectoris)
eTable 2. Results of Univariable and Multivariable Cox Proportional Hazard Analysis Demonstrating the Predictive Value of the Presence of any Coronary Plaque, High-Risk Plaque, and Significant Coronary Stenosis for the Outcome of Major Adverse Cardiovascular Events (Death, Non-Fatal Myocardial Infarction, or Hospitalization for Unstable Angina Pectoris)
eTable 3. Results of Univariable and Multivariable Cox Proportional Hazard Analysis Demonstrating the Predictive Value of High-Risk Plaque for the Outcome of Major Adverse Cardiovascular Events (Death, Non-Fatal Myocardial Infarction, or Hospitalization for Unstable Angina Pectoris) in Patient Subgroups
Customize your JAMA Network experience by selecting one or more topics from the list below.
Ferencik M, Mayrhofer T, Bittner DO, et al. Use of High-Risk Coronary Atherosclerotic Plaque Detection for Risk Stratification of Patients With Stable Chest Pain: A Secondary Analysis of the PROMISE Randomized Clinical Trial. JAMA Cardiol. 2018;3(2):144–152. doi:10.1001/jamacardio.2017.4973
Is high-risk plaque, as detected by coronary computed tomographic angiography, associated with incident major adverse cardiovascular events?
In this substudy of the PROMISE trial, we evaluated the presence of high-risk plaque in 4415 patients. High-risk plaque was present in 676 patients (15%) and carried a 70% increased risk of major adverse cardiovascular events independent of cardiovascular risk factors and obstructive coronary artery disease; detection was most useful in younger patients, women, and those with nonobstructive coronary artery disease.
The findings suggest the potential significance of detecting high-risk plaques in patients with stable ischemic heart disease; however, the low absolute rates of major adverse cardiovascular events and low positive predictive value of high-risk plaque detection might limit its clinical applicability.
Coronary computed tomographic angiography (coronary CTA) can characterize coronary artery disease, including high-risk plaque. A noninvasive method of identifying high-risk plaque before major adverse cardiovascular events (MACE) could provide practice-changing optimizations in coronary artery disease care.
To determine whether high-risk plaque detected by coronary CTA was associated with incident MACE independently of significant stenosis (SS) and cardiovascular risk factors.
Design, Setting, and Participants
This prespecified nested observational cohort study was part of the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. All stable, symptomatic outpatients in this trial who required noninvasive cardiovascular testing and received coronary CTA were included and followed up for a median of 25 months.
Core laboratory assessment of coronary CTA for SS and high-risk plaque (eg, positive remodeling, low computed tomographic attenuation, or napkin-ring sign).
Main Outcomes and Measures
The primary end point was an adjudicated composite of MACE (defined as death, myocardial infarction, or unstable angina).
The study included 4415 patients, of whom 2296 (52%) were women, with a mean age of 60.5 years, a median atherosclerotic cardiovascular disease (ASCVD) risk score of 11, and a MACE rate of 3% (131 events). A total of 676 patients (15.3%) had high-risk plaques, and 276 (6.3%) had SS. The presence of high-risk plaque was associated with a higher MACE rate (6.4% vs 2.4%; hazard ratio, 2.73; 95% CI, 1.89-3.93). This association persisted after adjustment for ASCVD risk score and SS (adjusted hazard ratio [aHR], 1.72; 95% CI, 1.13-2.62). Adding high-risk plaque to the ASCVD risk score and SS assessment led to a significant continuous net reclassification improvement (0.34; 95% CI, 0.02-0.51). Presence of high-risk plaque increased MACE risk among patients with nonobstructive coronary artery disease relative to patients without high-risk plaque (aHR, 4.31 vs 2.64; 95% CI, 2.25-8.26 vs 1.49-4.69). There were no significant differences in MACE in patients with SS and high-risk plaque as opposed to those with SS but not high-risk plaque (aHR, 8.68 vs. 9.31; 95% CI, 4.25-17.73 vs 4.21-20.61). High-risk plaque was a stronger predictor of MACE in women (aHR, 2.41; 95% CI, 1.25-4.64) vs men (aHR, 1.40; 95% CI, 0.81-2.39) and younger patients (aHR, 2.33; 95% CI, 1.20-4.51) vs older ones (aHR, 1.36; 95% CI, 0.77-2.39).
Conclusions and Relevance
High-risk plaque found by coronary CTA was associated with a future MACE in a large US population of outpatients with stable chest pain. High-risk plaque may be an additional risk stratification tool, especially in patients with nonobstructive coronary artery disease, younger patients, and women. The importance of findings is limited by low absolute MACE rates and low positive predictive value of high-risk plaque.
clinicaltrials.gov Indentifier: NCT01174550
Evaluation of stable chest pain often requires diagnostic testing with the goals of detecting obstructive coronary artery disease (CAD) and assessing the risk of a future major adverse cardiovascular event (MACE), defined as death, myocardial infarction, or unstable angina. Coronary computed tomography angiography (CTA) has developed into a reliable, noninvasive technique and a viable alternative to functional testing in outpatients with new onset of symptoms suggestive of obstructive CAD.1-5 The predictive value of coronary CTA for MACE is similar to that of conventional functional testing.4,5 The traditional assessment of coronary CTA for obstructive CAD provides prognostic information for MACE.6-8 However, more than half of MACEs occur in patients with nonobstructive CAD; coronary plaque detected by coronary CTA provides additional prognostic value in this group.8 The Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT) trial, which studied coronary plaques using intravascular ultrasound in survivors of acute coronary syndrome (ACS), found that plaque characteristics (eg, a thin-cap fibroatheroma and a plaque burden >70%) were associated with 2.5-fold to 5-fold increased risk of repeat events.9
Previous research using tissue samples and intravascular imaging has defined characteristics of coronary plaques (eg, a large necrotic lipid pool, a thin fibrous cap, and a large plaque burden) that are associated with sudden cardiac death and ACS.10,11 Coronary CTA can characterize coronary plaques, including the detection of high-risk features such as positive remodeling, low computed tomography (CT) attenuation, or napkin-ring sign.12,13 High-risk plaques were associated with advanced atherosclerotic plaque, thin-cap fibroatheroma, and large lipid pools, as well as with culprit lesions of ACS.13-19 Recent studies in Japanese patients with stable chest pain suggested that the presence of high-risk plaque on coronary CTA was associated with 5-fold to 8-fold increased risk of MACE.12,20-22 We performed standardized core laboratory assessment of coronary CTA in a large contemporary North American population of outpatients undergoing evaluation for new-onset stable chest pain in the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial (clinicaltrials.gov No. NCT01174550). We tested the hypothesis that the presence of high-risk plaque was associated with incident MACE independent of clinically significant stenosis (SS) and cardiovascular risk factors.
The PROMISE trial was a pragmatic comparative effectiveness trial that enrolled 10 003 patients at 193 sites in North America between July 2010 and September 2013. Details regarding the PROMISE study have been described elsewhere.4,23 The study enrolled stable symptomatic outpatients without known CAD who required noninvasive cardiovascular testing. Participants were randomly assigned to either the coronary CTA or functional testing group. Patient demographics and cardiovascular risk factors were documented at the time of enrollment. Atherosclerotic cardiovascular disease (ASCVD) and Framingham Heart Study risk scores were calculated.24,25 After randomization, follow-up visits were performed at 60 days at the study sites and centrally at 6-month intervals for a minimum of 1 year. 4,23 Local or central institutional review boards approved the study, and all participants provided written informed consent.
In our cohort study nested in the original PROMISE trial, we included all patients who were randomized to the coronary CTA arm of the trial and who received the initial diagnostic test as randomized. (Eligible participants were randomly assigned in a ratio of 1:1 to either the anatomical or functional diagnostic testing arm of the trial. A computer-generated permuted block randomization scheme with stratification by clinical site was used.4,23) We excluded patients who received other tests as their first test, did not undergo any diagnostic test, or received noncontrast CT testing only, as well as those for whom coronary CTA data sets were unavailable or were of nondiagnostic quality (Figure 1).
Coronary CTA images were acquired using either retrospectively electrocardiogram-gated or prospectively electrocardiogram-triggered protocols according to guidelines and local protocols using scanners from 4 vendors (Siemens, General Electric, Toshiba, and Philips) and different generations (64-row, 128-row, 256-row, 320-row, and dual source).26 The images were transferred to the core laboratory for the analysis at a cardiac image-viewing workstation (TeraRecon). Six readers with level 3 training in coronary CTA were randomly assigned data sets for analysis. A further 50 randomly selected coronary CTA data sets were analyzed by all 6 readers to determine interobserver agreement (high-risk plaque: κ = 0.56; ≥70% stenosis or left main ≥50% stenosis: κ = 0.69). The coronary CTA analysis was performed per coronary segment.27 Coronary segments with nondiagnostic image quality (1602 of 79 470; 2.0%) were treated as noninformative for the analysis.
Each evaluable coronary segment was assessed for the presence of stenosis. The severity of stenosis was quantified by visual estimation into 5 categories (0%, 1%-29%, 30%-49%, 50%-69%, or ≥70% stenosis).27 We defined SS as the presence of 70% stenosis or greater in any vessel or 50% stenosis or greater in the left main coronary artery. We performed a sensitivity analysis using the definition of 50% stenosis or greater in any coronary artery as SS. Nonobstructive CAD was defined as the presence of coronary plaque with no SS.
For each evaluable coronary segment, we noted the presence of plaque (calcified, noncalcified, or partially calcified; eFigure 1 in the Supplement).28 Each coronary segment with plaque was evaluated for the presence of high-risk plaque. High-risk plaque features were defined as positive remodeling (remodeling index, >1.1), low CT attenuation (mean CT number <30 HU), or napkin-ring sign (a ringlike peripheral higher attenuation with central low CT attenuation; eFigure 1 in the Supplement).12,16,18-21,29-31 Each patient was classified as having high-risk plaque if at least 1 high-risk plaque feature was present. We also performed sensitivity analyses using the definition of high-risk plaque as the presence of both positive remodeling and low CT attenuation, the presence of positive remodeling or low CT attenuation, and the presence of any 2 or 3 high-risk plaque features.12
The primary end point was a composite of time to MACE, the definition of which included death from any cause, myocardial infarction, and hospitalization for unstable angina. We performed a sensitivity analysis with MACE defined as the secondary composite end point of cardiovascular death, myocardial infarction, or hospitalization for unstable angina, and as the tertiary composite end point of death or myocardial infarction. An independent clinical events committee adjudicated all end point events in a blinded fashion on the basis of standard, prospectively determined definitions, as described previously.4,23
Continuous variables are presented as mean (SD) or median (interquartile range [IQR]). Categorical variables are presented as frequencies and percentages. Comparisons between groups were performed with the use of a 2-sample t test or a Wilcoxon rank-sum test for continuous variables and with a Fisher exact test for categorical variables. Interobserver agreement was calculated using the κ statistic. The Cox proportional hazards model was used to assess the relationship of the presence of high-risk plaque and time to the first clinical event (or censoring) for the composite end point. To appropriately account for heterogeneity among the participants, analyses were adjusted for a prespecified set of baseline covariates, including SS and ASCVD risk score or Framingham Heart Study risk score. Adjusted hazard ratios (aHRs) and 95% confidence intervals were computed using Cox models to characterize the relative risks of patients with high-risk plaque vs those without high-risk plaque. Cumulative event rates based on test results were computed using the Kaplan-Meier method. The C index (also known as the concordance statistic) and continuous net reclassification improvement was calculated using the risk prediction (incrisk) package in Stata (version 14.2, StataCorp).32 Bootstrap standard errors and 95% CIs were calculated using 10 000 bootstrap samples. The calibration of the model containing high-risk plaque, SS, and ASCVD risk score was tested using Grønnesby and Borgan test for goodness of fit. All P values were 2-sided, and were considered significant at the nominal .05 level. All statistical analyses were performed using Stata 14.2 (StataCorp).
The baseline characteristics of 4415 patients included in our study are summarized in Table 1, stratified by the presence of high-risk plaque. Patients with high-risk plaque, compared with those without the condition, were more often men (428 of 676, or 63.3%, vs 1704 of 3739, or 45.6%, P < .001), more often smokers (420 of 676, or 62.1%, vs 1836 of 3738, or 49.1%; P < .001), and had mean (SD) body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 29.4 (5.1) vs 30.6 (6.1) (P < .001). No other individual risk factors were associated with the presence of high-risk plaque. The mean (SD) number of risk factors was higher in patients with high-risk plaque (2.49 [1.10]) compared with patients without high-risk plaque (2.33 [1.07]). Patients with high-risk plaque compared with those without high-risk plaque had elevated median (IQR) ASCVD risk scores (13.9 [8.3-23.2] vs 10.5 [5.8-18.4]), and elevated median (IQR) Framingham Heart Study risk scores (21.6 [13.8-34.0] vs 16.2 [10.0-26.3]).
The presence of high-risk plaque was detected in 676 patients (15.3%). Of these patients, 628 (92.9%) had positive remodeling; 222 (32.8%) had low CT attenuation; 169 (25.0%) had napkin-ring sign; 179 (26.5%) had both positive remodeling and low CT attenuation; and 671 (99.3%) had at least 1 of the high-risk plaque features of positive remodeling and low CT attenuation plaque. The prevalence of high-risk plaque in subgroups was 10.9% for women vs 20.1% for men (P < .001), 13.7% for those under median age vs 16.9% for those at or above median age (P = .004); 17.1% for those with a BMI below the median value of 30.4 vs 13.6% for those with a BMI equal to or greater than the median (P = .001); 15.1% for those without diabetes vs 16.1% for those with diabetes (P = .47); 11.9% for patients reporting no tobacco use vs 18.6% for those reporting current or past tobacco use (P < .001); and 14.4% for non-Hispanic white people vs 15.5% for people of other races (P = .39).
The prevalence of high-risk plaque gradually increased with the increasing degree of stenosis (Table 2): no stenosis (0 of 1525 patients; 0%), 1% to 29% stenosis (186 of 1391 patients; 13.4%), 30% to 49% stenosis (196 of 884 patients; 22.2%), 50% to 69% (125 of 345 patients; 36.2%), and stenosis equal to or greater than 70% (169 of 270 patients; 62.6%). The presence of both high-risk plaque and SS was observed in 171 of the 4415 patients (3.9%). High-risk plaque without SS was present in 505 patients (11.4%), and SS without high-risk plaque in 105 patients (2.4%).
The primary outcome of composite MACE occurred in 131 of 4415 patients (total incidence, 3.0%). This included death from all causes (60 patients; 1.4%), cardiovascular death (31 patients; 0.7%), nonfatal myocardial infarction (24 patients; 0.5%), and hospitalization for unstable angina (47 patients; 1.1%) during a median (IQR) follow-up of 25 (18-34) months. Patients with high-risk plaque had an increased risk of MACE (43 of 676 patients, 6.4%) compared with patients without high-risk plaque (88 of 3739 patients, 2.4%; unadjusted HR, 2.73; 95% CI, 1.89-3.93) (eTable 1 in the Supplement). The sensitivity analysis using alternative definitions of high-risk plaque (eg, the presence of both positive remodeling and low CT attenuation, the presence of positive remodeling or low CT attenuation, or the presence of any 2 or 3 high-risk plaque features) rendered similar results (eTable 1 in the Supplement).
The association of high-risk plaque with MACE remained significant after adjustment for SS (defined as ≥70% stenosis in any coronary artery or ≥50% stenosis in the left main coronary artery) and ASCVD risk score (aHR, 1.72; 95% CI, 1.13-2.62) (Figure 2).
Furthermore, adding high-risk plaque to a baseline model that included SS and ASCVD risk score led to a significant continuous net reclassification improvement (0.34; 95% CI, 0.02-0.51). The C index did not increase significantly when a model including only ASCVD score and SS had high-risk plaque added to it (0.69 [95% CI, 0.63-0.74] vs 0.71 [95% CI, 0.66-0.76]; P = .12). A Grønnesby and Borgan test for goodness of fit of the model including ASCVD score, SS, and high-risk plaque was also nonsignificant, suggesting there was no gross model violation. The sensitivity, specificity, positive predictive value, and negative predictive value of high-risk plaque for MACE were 32.8%, 85.2%, 6.4%, and 97.6%, respectively.
Similar results were observed when SS was defined as stenosis equal to or greater than 50% in any coronary artery (HR, 1.58; 95% CI, 1.04-2.40); when Framingham Heart Study risk score was used for adjustment (aHR, 1.68; 95% CI, 1.10-2.56); when the secondary composite end point of cardiovascular death, myocardial infarction, or hospitalization for unstable angina was used (aHR, 1.63; 95% CI, 1.01-2.62) (eFigure 2A in the Supplement); and when the tertiary composite end point of death or myocardial infarction (aHR, 1.85; 95% CI, 1.10-3.09; eFigure 2B in the Supplement) was used as the outcome.
In patients with nonobstructive CAD, in whom most incidents of MACE occurred (86 of 131; 65.6%), the presence of high-risk plaque identified a subgroup with increased risk of MACE. Of 505 patients with high-risk plaque, 24 experienced MACE (4.8%; aHR, 4.31; 95% CI, 2.25-8.26) compared with just 62 of the 2109 patients with no high-risk plaque (2.9%; aHR, 2.64; 95% CI, 1.49-4.69; Figure 2; eTable 2 in the Supplement). In contrast, the increase of MACE risk was similar whether high-risk plaque was present or absent among patients with SS; 19 of 171 patients with high-risk plaque (11.1%; aHR, 8.68; 95% CI, 4.25-17.73) experienced these events, compared with 11 of 105 patients with no high-risk plaque (10.5%; HR, 9.31; 95% CI, 4.21-20.61; eFigure 3 in the Supplement).
We also performed multivariable Cox proportional hazards analyses adjusted for SS and ASCVD score in patient subgroups (Figure 3; eTable 3 in the Supplement). There was a stronger association of the presence of high-risk plaque with MACE in women (aHR, 2.41; 95% CI, 1.25-4.64) than in men (aHR, 1.40; 95% CI, 0.81-2.39). The association of high-risk plaque and MACE was also stronger in younger patients (aHR, 2.33; 95% CI, 1.20-4.51) than in older patients (aHR, 1.36; 95% CI, 0.77-2.39). In a subgroup of women younger than the median age of 59.6 years (n = 952), we found that 4 of 84 women with high-risk plaque (4.8%) vs 7 of the 868 with no high-risk plaque (0.8%) experienced MACE (aHR, 4.16; 95% CI, 1.00-17.28), suggesting a strong predictive value of high-risk plaque in this subgroup.
Our study demonstrated that the presence of high-risk plaque (as observed by signs such as positive remodeling, low CT attenuation, and napkin-ring sign) carried a 70% increased risk of future MACE in a large contemporary North American population of outpatients with stable chest pain, and that this risk was independent of cardiovascular risk factor burden and obstructive CAD. Detection of high-risk plaque added the most value for patients with nonobstructive CAD and those with a lower atherosclerosis burden such as younger patients and women. Our results demonstrate the clinical significance of detecting individual high-risk plaques relative to standard clinical risk factors and obstructive CAD. This suggests the potential to use this information to optimize management of this large group of patients.
Our observation of the independent predictive value of high-risk plaque for future MACE in a North American population with stable chest pain expands studies performed in Japanese populations that reported 5-fold to 8-fold increased risk of MACE in patients with high-risk plaque.12,20-22 Although our study concurred with observations that high-risk plaque was independently associated with MACE after adjusting for cardiovascular risk factors and SS, we could not confirm that high-risk plaque features might identify vulnerable lesions with a high positive predictive value for future MACE (aHR, 1.72). In part, this was because 43 of 676 patients with high-risk plaque (6.4%) experienced MACE.
Some of the differences could be explained by differences in risk profiles and clinical presentations in Japanese and North American populations (eg, lower BMIs and lower prevalence of statin treatment in the Japanese study cohorts, as well as the inclusion of some patients with CAD history in the Japanese studies). The lower predictive value of high-risk plaque also reflects temporal changes in cardiovascular disease during the last 2 decades, which includes a shift in acute coronary syndome presentations from myocardial infarctions with ST-segment elevation to those without ST-segment elevation, decrease in plaque ruptures in culprit lesions of acute coronary syndromes, and more stable characteristics of atherosclerotic plaques (eg, smaller lipid cores and less intraplaque inflammation).33 These changes can be explained by increased use of lipid-lowering therapies (statins), better blood pressure control, and decreased prevalence of smoking; they are responsible for low MACE rates in contemporary cardiovascular clinical trials.33
However, the most striking difference, which might have significantly affected the large difference in the aHRs between our study and those completed in Japan, is the weak association of SS with MACE in the Japanese studies (aHR, 1.6-1.7). This is in contrast with our data (which found an aHR of approximately 9 for SS) and other studies from North America and Europe (which reported aHR values ranging from 3 to 9).6,7,34,35 As a result of the strong association of stenosis with MACE, there was no incremental value in high-risk plaque detection for the prediction of MACE in patients with SS. We speculate that in patients with SS the presence of stenosis plays an important role in MACE in the short term. Indeed, we observed that a significant portion of MACE occurred in the first 6 months after coronary CTA (Figure 2). In contrast, in patients with nonobstructive CAD and high-risk plaque, we found an increase in MACE more than 12 months after coronary CTA, suggesting that plaque progression and rupture may have played a role in the progression to these events.
Because the PROMISE trial had a fairly low prevalence of obstructive CAD, the present cohort included a large number of patients who had nonobstructive CAD. This meant the study identified a large additional group of at-risk patients, in whom over half of MACEs occurred.8 Our results are in agreement with extensive research in interventional cardiology that has found that a significant number of MACEs occur at locations in the coronary artery tree where previously no obstructive CAD was present.36-38 Indeed, the presence of high-risk plaque doubles the risk of MACE in the group of patients with nonobstructive CAD, and this provides considerably more information. Since the presence of high-risk plaque can be easily determined during routine evaluation of coronary CTA and because it permits risk reclassification especially in younger patients and women, information on the presence of high-risk plaque should be included in standardized reports in accordance with the current guideline recommendations.39
The large size of our population permitted subgroup analyses that provided additional insights into the role of high-risk plaque for MACE prediction. We observed that the predictive value of high-risk plaque was stronger in younger patients and women. Women with CAD tend to have lower coronary plaque burden but also smaller size of coronary arteries, which may lead to symptomatic disease with lower plaque burden or thrombus load.40-45 Previous studies of differences in coronary plaque development in men and women have suggested that lower prevalence of plaque ruptures and thin-cap fibroatheroma but higher prevalence of plaque erosions exist in women; however, these results have not been consistent across studies.41,46-49 Sex-based differences in plaque size and composition have been more pronounced in younger women and more attenuated in women older than 65 years.43,49 We speculate that when high-risk plaques are present in younger women, they portend a higher risk of future MACE. Furthermore, younger patients and women have a lower prevalence of obstructive CAD, and thus, consistent with our findings, high-risk plaque may be most helpful for risk stratification in patients without SS.
The results of our study challenge the feasibility of local therapies for high-risk plaque. We found that only 6.4% of patients with high-risk plaque developed MACE and that, among 131 patients with MACEs, 88 patients (67.2%) had no high-risk plaque. These results are similar to observations from the PROSPECT trial, in which only 26 of 595 patients (4.9%) with thin-cap fibroatheromata experienced the development of culprit lesions of acute coronary syndrome.9 Therefore, local interventional therapies for high-risk plaque may be of limited value. Overall, the presence of high-risk plaque, especially in those with nonobstructive CAD, may constitute an additional risk stratification tool guiding management, including lifestyle modification (eg, diet and exercise) and pharmacologic treatments (eg, treatment with lipid-lowering and antiplatelet therapies).
In the setting of low MACE rates observed in the PROMISE trial, HRs may inflate the importance of our observations. This is especially true given the low positive predictive value of high-risk plaque for MACE. The options for changes in preventive therapies (eg, aspirin or statin) based on the detection of high-risk plaque by coronary CTA are limited, and no data on whether such interventions would change long-term outcomes are available from our study. The PROMISE trial was not a study of natural history, and patients were treated based on coronary CTA results, which might have affected MACE. We performed a qualitative analysis of high-risk plaque with simple manual measurements that can be easily incorporated into clinical practice. An identical approach was used by other investigators studying the predictive value of high-risk plaque.12,21 Quantitative plaque assessment is feasible but remains time-consuming, not widely used in clinical practice, and of unproven value.
In a large contemporary North American population of outpatients with stable chest pain, noninvasive detection of high-risk plaque improved risk assessment for MACE. The detection of high-risk plaque added the most value in patients with nonobstructive CAD, younger patients, and women. High-risk plaque may constitute an additional risk stratification tool for clinical management. However, because absolute event rates were low and the positive predictive value of high-risk plaque was diminished, the findings may be of limited applicability to clinical management strategies.
Corresponding Author: Maros Ferencik, MD, PhD, MCR, Knight Cardiovascular Institute, Oregon Health and Science University, 3180 Sam Jackson Park Rd, Mail Code UHN62, Portland, OR 97239 (firstname.lastname@example.org).
Accepted for Publication: November 14, 2017.
Published Online: January 10, 2018. doi:10.1001/jamacardio.2017.4973
Author Contributions: Drs Ferencik and Hoffmann had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Ferencik, Bittner, Puchner, Lu, Meyersohn, Udelson, Douglas, Hoffmann.
Acquisition, analysis, or interpretation of data: Ferencik, Mayrhofer, Bittner, Emami, Puchner, Lu, Meyersohn, Ivanov, Adami, Patel, Mark, Udelson, Lee, Hoffmann.
Drafting of the manuscript: Ferencik, Puchner.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Ferencik, Mayrhofer, Bittner, Meyersohn, Ivanov, Lee.
Obtained funding: Douglas, Hoffmann.
Administrative, technical, or material support: Ferencik, Puchner, Lu, Meyersohn, Adami, Douglas, Hoffmann.
Study supervision: Ferencik, Bittner, Puchner, Patel, Udelson, Douglas, Hoffmann.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Ferencik reports receiving a grant from the American Heart Association. Dr Bittner was supported by the National Institutes of Health/National Heart, Lung, and Blood Institute (grant 5K24HL113128). Dr Lu reports receiving grant support from the American Roentgen Ray Society Scholarship during the conduct of the study and personal fees from PQBypass outside the submitted work. Dr Meyersohn was supported by the National Institutes of Health/National Heart, Lung, and Blood Institute (grant T32 HL076136). Dr Patel reports receiving grants from HeartFlow Technologies, AstraZeneca, Bayer, and Janssen and personal fees from Bayer, outside the submitted work. Dr Mark reports receiving grants from the National Institutes of Health during the conduct of the study, as well as personal fees from Medtronic, Inc, CardioDx, and St. Jude Medical, and grants from Eli Lilly and Company, Bristol-Myers Squibb, Gilead Sciences, Inc, AGA Medical Corporation, Merck & Company, Oxygen Therapeutics, and AstraZeneca outside the submitted work. Dr Udelson reports grants from National Heart, Lung, and Blood Institute during the conduct of the study. Dr Lee reports grants from National Heart, Lung, and Blood Institute during the conduct of the study. Dr Douglas reports receiving grant support from HeartFlow and service on a data and safety monitoring board for GE HealthCare outside the submitted work. Dr Hoffmann reports receiving grants from the American College of Radiology Imaging Network and HeartFlow Technologies, Medimmune, Kowa Ltd, Siemens Healthcare, and HeartFlow Inc. outside the submitted work. No other disclosures are reported.
Funding/Support: The PROMISE trial was funded by the National Heart, Lung, and Blood Institute (grants R01HL098237, R01HL098236, R01HL98305, and R01HL098235).
Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The views expressed in this article do not necessarily represent the official views of National Heart, Lung, and Blood Institute.
Additional Contributions: We thank all the patients who participated in PROMISE, and Sarah Hayden, Peter Hoffmann, Beth Martinez, Stephanie Wu, and Qinghong Yang of Duke Clinical Research Institute at the Duke University School of Medicine in Durham, North Carolina, for their important and uncompensated contributions.
Create a personal account or sign in to: